CCL

Összesen 6 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM103936
035-os BibID:(WoS)000868254300009 (Scopus)85143055930
Első szerző:Aggarwal, Rohit
Cím:Trial of Intravenous Immune Globulin in Dermatomyositis / Aggarwal Rohit, Charles-Schoeman Christina, Schessl Joachim, Bata-Csörgő Zsuzsanna, Dimachkie Mazen M., Griger Zoltan, Moiseev Sergey, Oddis Chester, Schiopu Elena, Vencovsky Jiri, Beckmann Irene, Clodi Elisabeth, Bugrova Olga, Dankó Katalin, Ernste Floranne, Goyal Namita A., Heuer Marvin, Hudson Marie, Hussain Yessar M., Karam Chafic, Magnolo Nina, Nelson Ronald, Pozur Nataliia, Prystupa Liudmyla, Sárdy Miklós, Valenzuela Guillermo, van der Kooi Anneke J., Vu Tuan, Worm Margitta, Levine Todd, ProDERM Trial Group
Dátum:2022
ISSN:0028-4793
Megjegyzések:Background: Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. Methods: We conducted a randomized, placebo-controlled trial involving patients with active dermatomyositis. The patients were assigned in a 1:1 ratio to receive IVIG at a dose of 2.0 g per kilogram of body weight or placebo every 4 weeks for 16 weeks. The patients who received placebo and those without confirmed clinical deterioration while receiving IVIG could enter an open-label extension phase for another 24 weeks. The primary end point was a response, defined as a Total Improvement Score (TIS) of at least 20 (indicating at least minimal improvement) at week 16 and no confirmed deterioration up to week 16. The TIS is a weighted composite score reflecting the change in a core set of six measures of myositis activity over time; scores range from 0 to 100, with higher scores indicating greater improvement. Key secondary end points included at least moderate improvement (TIS ?40) and major improvement (TIS ?60), and change in score on the Cutaneous Dermatomyositis Disease Area and Severity Index. Results: A total of 95 patients underwent randomization: 47 patients were assigned to the IVIG group, and 48 to the placebo group. At 16 weeks, 79% of the patients in the IVIG group (37 of 47) and 44% of those in the placebo group (21 of 48) had a TIS of at least 20 (difference, 35 percentage points; 95% confidence interval, 17 to 53; P<0.001). The results with respect to the secondary end points, including at least moderate improvement and major improvement, were generally in the same direction as the results of the primary end-point analysis, except for the change in creatine kinase level (an individual core measure of the TIS), which did not differ meaningfully between the two groups. Over 40 weeks, 282 treatment-related adverse events occurred in the IVIG group, including headache (in 42% of patients), pyrexia (in 19%), and nausea (in 16%). A total of 9 serious adverse events that were considered to be related to IVIG occurred, including 6 thromboembolic events. Conclusions: In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, NCT02728752.).
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:New England Journal Of Medicine. - 387 : 14 (2022), p. 1264-1278. -
További szerzők:Charles-Schoeman, Christina Schessl, Joachim Bata-Csörgő Zsuzsanna Dimachkie, Mazen M. Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Moiseev, Sergey Oddis, Chester V. Schiopu, Elena Vencovsky, Jiri Beckmann, Irene Clodi, Elisabeth Bugrova, Olga Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Ernste, Floranne Goyal, Namita A. Heuer, Marvin Hudson, Marie Hussain, Yessar M. Karam, Chafic Magnolo, Nina Nelson, Ronald Pozur, Nataliia Prystupa, Liudmyla Sárdy Miklós Valenzuela, Guillermo van der Kooi, Anneke J. Vu, Tuan Worm, Margitta Levine, Todd ProDERM Trial Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM061948
Első szerző:Bodoki Levente (PhD hallgató)
Cím:Inclusion body myositis - a case based clinicopathological update / Bodoki Levente, Nagy-Vincze Melinda, Griger Zoltán, Csonka Tamás, Murnyák Balázs, Kurucz Andrea, Dankó Katalin, Hortobágyi Tibor
Dátum:2014
ISSN:1895-1058 1644-3640
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Central European Journal of Medicine. - 9 : 1 (2014), p. 80-85. -
További szerzők:Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Csonka Tamás (1984-) (pathológus) Murnyák Balázs (1986-) (molekuláris biológus, genetikus) Kurucz Andrea (1984-) (orvos) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Hortobágyi Tibor (1965-) (patológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM047187
035-os BibID:PMID:22732951
Első szerző:Labirua-Iturburu, Ane
Cím:Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome : clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature / Ane Labirua-Iturburu, Albert Selva-O'Callaghan, Melinda Vincze, Katalin Dankó, Jiri Vencovsky, Benjamin Fisher, Peter Charles, Maryam Dastmalchi, Ingrid E. Lundberg
Dátum:2012
ISSN:0025-7974
Megjegyzések:Autoantibodies against several aminoacyl-transfer-RNA synthetases have been described in patients with myositis; anti-threonyl-tRNA synthetase (anti-PL-7) is one of the rarest. We describe the clinical and laboratory characteristics of a cohort of European anti-PL-7 patients, and compare them with previously reported cases. This multicenter study of patients positive for anti-PL-7, identified between 1984 and 2011, derives from the EUMYONET cohort. Clinical and serologic data were obtained by retrospective laboratory and medical record review, and statistical analyses were performed with chi-squared and Fisher exact tests. Eighteen patients, 15 women, were anti-PL-7 antibody positive. Median follow-up was 5.25 years (interquartile range, 2.8-10.7 yr), and 4 patients died. All patients had myositis (12 polymyositis, 5 dermatomyositis, and 1 amyopathic dermatomyositis), 10 (55.6%) had interstitial lung disease, and 9 (50%) had pericardial effusion. Occupational exposure to organic/inorganic particles was more frequent in patients with interstitial lung disease than in the remaining patients (5 of 10 vs. 1 of 7; p = 0.152), although the difference was not significant. Concurrent autoantibodies against Ro60 and Ro52 were seen in 8 of 14 (57%) patients studied. In the literature review the most common manifestations of anti-PL-7 antisynthetase syndrome were interstitial lung disease (77%), myositis (75%), and arthritis (56%). As in other subsets of the antisynthetase syndrome, myositis and interstitial lung disease are common features of the anti-PL-7 antisynthetase syndrome. In addition, we can add pericarditis as a possible manifestation related to anti-PL-7 antibodies.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Medicine 91 : 4 (2012), p. 206-211. -
További szerzők:Selva-O'Callaghan, Albert Nagy-Vincze Melinda (1985-) (orvos) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Vencovsky, Jiri Fisher, Benjamin Charles, Peter Dastmalchi, Maryam Lundberg, Ingrid
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM061954
Első szerző:Murnyák Balázs (molekuláris biológus, genetikus)
Cím:Inclusion body myositis : pathomechanism and lessons from genetics / Balázs Murnyák, Levente Bodoki, Melinda Vincze, Zoltán Griger, Tamás Csonka, Rita Szepesi, Andrea Kurucz, Katalin Dankó, Tibor Hortobágyi
Dátum:2015
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Open Medicine 10 (2015), p. 188-193. -
További szerzők:Bodoki Levente (1986-) (PhD hallgató) Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Csonka Tamás (1984-) (pathológus) Szepesi Rita (1975-) (neurológus) Kurucz Andrea (1984-) (orvos) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Hortobágyi Tibor (1965-) (patológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM111641
035-os BibID:(scopus)85160027968 (cikkazonosító)1168359
Első szerző:Vincze Anett
Cím:Pruritogenic molecules in the skin of patients with dermatomyositis / Vincze Anett, Herczeg-Lisztes Erika, Szabó Katalin, Béldi Tibor Gábor, Nagy-Vincze Melinda, Pór Ágnes, Varga József, Dankó Katalin, Biró Tamás, Tóth Balázs István, Griger Zoltán
Dátum:2023
ISSN:2296-858X
Megjegyzések:Introduction: Pruritus is a common excruciating symptom in systemic autoimmune diseases such as dermatomyositis (DM) but the pathogenesis is not fully understood. We intended to investigate the targeted expression analysis of candidate molecules involved in the development of pruritus in lesional vs. non-lesional skin samples of patients affected with active DM. We looked for correlations between the investigated pruriceptive signaling molecules, disease activity, and itching sensation of DM patients. Methods: Interleukins (IL-33 and IL-6), tumor necrosis factor ? (TNF-?), peroxisome proliferator-activated receptor ? (PPAR-?), and ion channels belonging to the transient receptor potential (TRP) family were analyzed. The expression of TNF-?, PPAR-?, IL-33, IL-6, and TRP channels in lesional DM skin was evaluated by RT-qPCR and immunohistochemistry and was compared with non-lesional DM skin samples. Pruritus, disease activity, and damage of DM were evaluated by the 5-D itch scale and Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), respectively. Statistical analysis was performed with IBM SPSS 28 software. Results: A total of 17 active DM patients participated in the study. We could show that the itching score was positively correlated with the CDASI activity score (Kendall's tau-b = 0.571; p = 0.003). TNF-? gene expression was significantly higher in lesional DM skin than in non-lesional DM skin (p = 0.009) and differed in the subgroups of patients with different itch intensities (p = 0.038). The mRNA expression of lesional IL-6 correlated positively with 5-D itch and CDASI activity score (Kendall's tau-b = 0.585; p = 0.008 and 0.45; p = 0.013, respectively). TRPV4 expressions were positively correlated with CDASI damage score (Kendall's tau-b = 0.626; p < 0.001), but the mRNA expressions of the TRP family, PPAR-?, IL-6, and IL-33 were not different in lesional and non-lesional samples. Immunohistochemistry analysis did not find significant alterations in the expressions of TNF-?, PPAR-?, IL-6, and IL-33 in lesional and non-lesional regions. Discussion: Our results argue that cutaneous disease activity, TNF-?, and IL-6 might play a central role in DM-associated itch, while TRPV4 plays a central role in tissue regeneration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
dermatomyositis
inflammatory myopathies
itch
pruritus
TRP channels
TNF-α
IL-6
Megjelenés:Frontiers in Medicine. - 10 (2023), p. 1168359. -
További szerzők:Lisztes Erika (1986-) (élettanász) Szabó Katalin (1991-) (orvos) Béldi Tibor (1994-) (orvos) Nagy-Vincze Melinda (1985-) (orvos) Pór Ágnes Varga József (1955-) (fizikus) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus) Bíró Tamás (1968-) (élettanász) Tóth István Balázs (1978-) (élettanász) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus)
Pályázati támogatás:134791
OTKA
120187
OTKA
EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
Bolyai János Kutatási Ösztöndíj
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM081379
Első szerző:Zilahi Erika (molekuláris biológus)
Cím:Dysregulated expression profile of myomiRs in the skeletal muscle of patients with polymyositis / Erika Zilahi, Zsuzsanna Adamecz, Levente Bodoki, Zoltán Griger, Szilárd Póliska, Melinda Nagy-Vincze, Katalin Dankó
Dátum:2019
Megjegyzések:MicroRNA (miRNA) research has intensively developed over the past decade. Characterization of dysregulated miRNA expression profiles could give a better understanding of the development of pathological conditions and clinical disorders, such as autoimmune diseases with polygenic etiology, including idiopathic inflammatory myopathies (IIMs). IIMs are a group of rare autoimmune disorders characterized by skeletal weakness and inflammation. Polymyositis (PM) is one of the conditions of autoimmune myopathies with proximal skeletal muscle weakness. A novel group of miRNAs, known as myomiRs are described as striated muscle-specific or muscle-enriched miRNAs. They are involved in myoblast proliferation/differentiation as well as muscle regeneration. To determine the role of myomiRs in the development and progression of PM, we performed an initial skeletal muscle miRNA profiling using microarray technique at diagnosis. The aim of the study was to examine myomiRs expression profile in patients with PM in order to remark the association between the dysregulated myomiRs' expression and the development of the disease. As a results of microarray investigation, most of the myomiRs showed altered expression patterns in the muscle samples of PM patients compared to controls. These results suggest that myomiRs, especially miR-1, miR-133a, miR-208b, miR-486, and miR-499 function in a network, and are associated with the development of PM.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
autoimmune disease
microarray
myomiRs
polymyositis
Megjelenés:The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine. - 30 : 2 (2019), p. 237-245. -
További szerzők:Adamecz Zsuzsanna Bodoki Levente (1986-) (PhD hallgató) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Póliska Szilárd (1978-) (biológus) Nagy-Vincze Melinda (1985-) (orvos) Dankó Katalin (1952-2021) (belgyógyász, allergológus és klinikai immunológus)
Internet cím:Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.